Yahoo Finance

Prolocor Announces Publication in Journal of Invasive Cardiology. Prolocor pFCG Test is a Powerful Prognostic Marker of Ischemic Risk Early After Myocardial Infarction (MI).

The hazard ratio (HR) for the primary endpoint was (3.84, p = 0.0009) in the first month The Prolocor pFCG™ test has the potential to help providers reduce 30-day readmission rates for Acute MI, ...
Yahoo Finance

Prolocor Announces Publication of Confirmatory Results From Multicenter 800 Patient Study in the Journal of the American College of Cardiology (JACC)

Dr. David Schneider, Prolocor Co-Founder and Chief Scientific Officer said, "I would like to thank the investigators and patients for their participation in this important study. The Prolocor pFCG ® ...
PharmiWeb

Prolocor to Present New Clinical Evidence at ACC 24 Supporting the Use of PLATELET FCɣRIIA (PFCG) as a Key Tool in Individualizing Dual Antiplatelet Therapy (DAPT)

PHILADELPHIA, PA / ACCESSWIRE / February 20, 2024 / Prolocor, Inc., a healthcare startup developing an innovative precision diagnostic test with the goal of predicting the risk of thrombosis by ...